Make sure you read this paper Klein. JJ often refers to it as the Sidwell paper. It compares Poly IC and ampligen and not only does ampligen have a much better safety profile it has anti-viral propertied that poly ic does not.
TLR3 Is Essential for the Induction of Protective Immunity against Punta Toro Virus Infection by the Double-Stranded RNA (dsRNA), Poly(I:C12U), but not Poly(I:C): Differential Recognition of Synthetic dsRNA Molecules1
Right, all you need to do is google cancer vaccine to see the anticipation on these new technologies. Just like the lung cancer guy in LA said, there is no doubt the research community is excited about the promise of these adjuvant, peptide vaccines! Much anticipation!
Luc, you are such a big dope. Anyone can go read the pr's and papers written by U of Penn and U of WA. They are obviously exited, and JJ and I are excited! Clinical,trials are not usually referred to as "boiler rooms"
Yes, that's a good way to put it teaching the immune system to remember, tlr3 bridges adaptive and innate. Fabulous, and would be huge.
Yep, I think the gmcsf addition is big pharma looking to,justify a drug. I suppose you could look at gmcsf as the standard of care, but only in pharma s eyes.
Good stuff JJ
Mice receiving IN Ampligen at −4 and +24 HPI failed to show a significant reduction of bioluminescent signal compared to untreated mice or to mice receiving IP Ampligen at +24 HPI (Figure 4D). Pathological analysis did identify reduced levels of encephalitic disease reduced levels of viral antigen than those compared to wild type infection but still greater than levels seen with IP Ampligen treatment (Figure 4D). In addition, two mice were given a vaccine dose of TC83 21 days prior to TC83-Luciferase challenge. They were imaged following IP luciferin injection and presented with no signal throughout the study (Figure 4A). Pathological analysis of the brain identified no signs of disease or viral antigen present in the slides at 6 DPI (Figure 4B). Following therapeutic and prophylactic treatments with an immune enhancer, our model allowed rapid efficacy assessment. The IVIS system was able to quickly and accurately identify signal reduction or complete inhibition provided by Ampligen and TC83 immunization before any clinical disease development was detected in unprotected mice.
Yahoo is cutting off most of it, will try a different section
Hey JJ, I don't recall seeing this study posted. Has this been posted? It is from 2011, and these are mice that are given intranasal inoculations against viral challenges.... some containing ampligen. unsurprisingly, Ampligen provided amazing protection.
Ampligen antiviral treatment and vaccine analysis
The IVIS system is an ideal system to identify and complete initial tests of potential vaccines and antiviral candidates against VEEV. Due to CNS invasion being a key aspect for VEEV encephalitic disease, further development of the TC83-Luciferase infection model is a perfect test system to develop a non-invasive means to test therapeutics. Accordingly, ICR mice were given Ampligen, a TLR-3 agonist that protects against lethal TC83 challenge [22–24] through either an IP or IN route of administration. Mice in the group receiving IP Ampligen at −4 and +24 hours showed no bioluminescent signal throughout the period of the study (Figure 3A) and viral titer analysis from the brain showed 2 out of 3 mice with no detectable virus load by 6 DPI. Histochemical analysis confirmed no signs of encephalitis or meningitis at 6 DPI. Mice receiving IP Ampligen at +24hpi showed a significantly reduced (p
ROFL! the snakes don't seem to have an explanation nor do they want to talk about the million shares now lost. Their big thanksgiving/tax sale play produced nothing.
ROFL, oh look - it's big talking luc. OK luc, let me know when you have the escrow account set up to deposit funds. Send me an email with the details and I'll check it out with the escow agent.
Congratulations Klein! You have now officially arrived --- your own personal stalking troll.
Yup, and Thanksgiving week is a favorite because traders are on vacation, w/ light trading. All you need do is look at two years ago. Last year was an exception because of the NDA.
"The Heb science is meaningless for all applictions"
So, so stoopid in light of advancing NIH grants that pay for HEB clinical trials. The really funny thing is -- is that you must think people are really stupid in order to believe your complete crock of bs. I guarantee you, no one buys your bs. It's hilarious!
Carry on. LOL